Active Biotech AB Interim report January - September 2016

LUND, Sweden, Nov. 11, 2016 -- Laquinimod

• The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
• The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017
• The study results from the pivotal clinical Phase 2 ARPEGGIO study, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the second half of 2017
• Preclinical results concerning laquinimod were presented at the ECTRIMS 2016 Congress held in London, UK, on September 14-17, 2016
• Special Protocol Assessment (SPA) for laquinimod rescinded after discussions with the FDA

ANYARA     

• Licensing agreement entered into with NeoTX Therapeutics Ltd

Tasquinimod, Paquinimod (57-57) and SILC (ISI)

• Out-licensing activities are continuing

New share issue 

• The Board of Directors has today decided, based on the authorization granted by the Annual General Meeting, to implement a rights issue totaling approximately SEK 55 M
• The issue is at no cost guaranteed in full by the company's largest owner MGA Holding AB

Financial summary

• Operating costs reduced by 67 % (SEK 107.4 M) compared with 2015
• Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017
  
  

For further information, please contact:     

The report is also available at www.activebiotech.com.

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/2d930325-016d-4aa6-8819-12468608eb0b